insights_auto
Miks on NOVO-B tõusnud? 2,93%?
Uurige põhjalikumaltchevron_right
NOVO-B:CPH
Novo Nordisk A/S
263,45Â DKK
arrow_upward
+2,93%(+7,50) 1 p
15. okt, 17:00:00 GMT +2 · DKK
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse NOVO-B põhistatistika genereerimine…
Ava
255,50Â DKK
Kõrge
263,45Â DKK
Madal
254,25Â DKK
Turu kapit.
870,08Â mld
Keskm. maht
5,18Â mln
Maht
0,00
52 näd kõrgeim
409,95Â DKK
52 näd madalaim
224,25Â DKK
Käibivad aktsiad
3,39Â mld
Töötajate arv
67Â tuh
Ava
255,50Â DKK
Kõrge
263,45Â DKK
Madal
254,25Â DKK
Turu kapit.
870,08Â mld
Keskm. maht
5,18Â mln
Maht
0,00
52 näd kõrgeim
409,95Â DKK
52 näd madalaim
224,25Â DKK
Käibivad aktsiad
3,39Â mld
Töötajate arv
67Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Foreign Policy Journal
·
13 minuti eest
Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount
TradingKey
·
7 tunni eest
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Traders Union
·
12 tunni eest
Why is Novo Nordisk stock up 3.2% today?
ad-hoc-news.de
·
17 tunni eest
Novo Nordisk stock gains 1.12 percent ahead of November 4 results
Profiil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Teave üksuse Novo Nordisk A/S kohta
TegevjuhtMaziar Mike Doustdar
Töötajad66,7 tuh
Asutatud1923
PeakontoridBagsværd, Pealinna piirkond, Taani
Sektor-
Veebisaitnovonordisk.com